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Abstract
Background: Cardiac fibroblasts, together with cardiomyocytes, occupy the majority of
cells in the myocardium and are involved in myocardial remodeling. The lysophospholipid
mediator sphigosine-1-phosphate (S1P) regulates functions of cardiovascular cells through
multiple receptors including S1PR1–S1PR3. S1PR1 but not other S1P receptors was upre-
gulated in angiotensin II-induced hypertrophic hearts. Therefore, we investigated a role of
S1PR1 in fibroblasts for cardiac remodeling by employing transgenic mice that overex-
pressed S1PR1 under the control of α-smooth muscle actin promoter. In S1PR1-transgenic
mouse heart, fibroblasts and/or myofibroblasts were hyperplastic, and those cells as well as
vascular smooth muscle cells overexpressed S1PR1. Transgenic mice developed bi-ven-
tricular hypertrophy by 12-week-old and diffuse interstitial fibrosis by 24-week-old without
hemodynamic stress. Cardiac remodeling in transgenic mice was associated with greater
ERK phosphorylation, upregulation of fetal genes, and systolic dysfunction. Transgenic
mouse heart showed increased mRNA expression of angiotensin-converting enzyme and
interleukin-6 (IL-6). Isolated fibroblasts from transgenic mice exhibited enhanced generation
of angiotensin II, which in turn stimulated IL-6 release. Either an AT1 blocker or angiotensin-
converting enzyme inhibitor prevented development of cardiac hypertrophy and fibrosis,
systolic dysfunction and increased IL-6 expression in transgenic mice. Finally, administra-
tion of anti-IL-6 antibody abolished an increase in tyrosine phosphorylation of STAT3, a
major signaling molecule downstream of IL-6, in the transgenic mouse heart and prevented
development of cardiac hypertrophy in transgenic mice. These results demonstrate a pro-
moting role of S1PR1 in cardiac fibroblasts for cardiac remodeling, in which angiotensin II—
AT1 and IL-6 are involved.
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Introduction
Increasing evidence indicates that cardiac hypertrophy is an independent risk factor for the
development of heart failure [1]. Initially, cardiac hypertrophy is a physiological adaptation of
the heart against increased workload to maintain normal heart function. However, sustained
pathological hypertrophic stimuli induce cardiomyocyte apoptosis and interstitial fibrosis,
which result in cardiac dysfunction [2]. Besides mechanical stresses, several neurohumoral fac-
tors acting via G protein-coupled receptors, which include angiotensin II (Ang II), endothelins
and catecholamines, have been identified as potent inducers of cardiac hypertrophy [3].
Sphingosine-1-phosphate (S1P), a lysophospholipid mediator, exerts pleiotropic actions
including cell proliferation, migration, differentiation and cell-cell adhesion [4]. The actions of
S1P are mediated by S1P-specific G protein-coupled receptor family comprising S1PR1 to
S1PR5. Cardiomyocytes express S1PR1, S1PR2, and S1PR3. An early study [5] in neonatal rat
cardiomyocytes demonstrated that S1P did not induce hypertrophy in vitro although structur-
ally related sphingosylphosphorylcoline was able to induce hypertrophy, whereas other studies
[6] showed that S1P induced hypertrophy of rat and mouse cardiomyocytes via S1PR1. How-
ever, there have been only a few in vivo studies that explored roles of S1P receptors in cardiac
remodeling [7]. We recently reported that mice that overexpress the S1P-synthesizing enzyme
sphingosine kinase (SphK)-1 developed progressive myocardial fibrosis without hypertrophy,
suggesting a role of S1P for cardiac remodeling in vivo [8].
Non-myocytes, predominantly fibroblasts, account for 60–70% of the cell number in the
myocardium although cardiomyocytes occupy the bulk of myocardial mass, and are critical to
maintain normal heart function through controlling extracellular matrix turnover and serving
electro-mechanical functions [9]. Cardiac fibroblasts release paracrine and autocrine media-
tors, which include endothelin-1, Ang-II, tumor necrosis factor-α and transforming growth
factor-β (TGF-β), into the microenvironment. These factors act on cardiomyocytes, inflamma-
tory cells and fibroblasts themselves, contributing to cardiac remodeling. The phenotype of
fibroblasts can change from a quiescent one in the normal heart to a proliferative, migratory
and secretory one as observed, for example, after myocardial infarction [10]. Fibroblasts,
which exhibit the latter phenotype and express contractile proteins including α-smooth muscle
actin (αSMA), are termed myofibroblasts and implicated in fibrosis in various organs includ-
ing heart.
Cardiac fibroblasts express S1PR1, S1PR2 and S1PR3 [11]. Among these, S1PR1 is coupled
exclusively to Gi to stimulate Ras/extracellular signal-regulated kinase (ERK), phsphoinositide
3-kinase/Akt and Rac pathways, which promote cell proliferation and migration. We observed
that S1PR1 was expressed in cardiac fibroblasts and upregulated in the hypertrophic heart of
mice receiving Ang II infusion. Previous study shows that Ang II increases the expression of
αSMA in fibroblast [12]. Ang II infusion also increased αSMA expression in hearts. Therefore,
we generated mice that overexpress S1PR1 transgene under the control of αSMA promoter to
study the role of S1PR1 in cardiac fibroblast during cardiac remodeling in vivo. We found in
the transgenic (TG) mice that augmented S1PR1 signaling in myofibroblasts led to the develop-
ment of pathological cardiac hypertrophy with interstitial fibrosis, which was mediated through
the paracrine actions of Ang II and interleukin-6 (IL-6) released by myofibroblasts. The trans-
genic mice provide a new model of Ang II-dependent hypertrophy without pressure overload.
Materials and methods
Generation of transgenic mice overexpressing S1PR1 (S1PR1-TG mice)
The expression plasmid that drives S1PR1 expression under αSMA promoter was constructed
as follows: Approximately 4700-bp EcoRI-BamHI fragment of human αSMA promoter DNA
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from pBS-HSMA-EA4.7 (kindly donated by Dr. T. Miwa in Osaka University) was ligated
onto the mammalian expression vector pCAGGS, in which the unique Hind III site had been
replaced by Not I site, at EcoRI site. The 1500-bp Stu I-Bgl II fragment of rat S1PR1 cDNA
encoding the entire coding sequence, which was blunted and Bst XI adaptor-ligated, was
ligated onto pCAGGS at Bst XI site. The ~8500bp linearized Sal I-Not I fragment of the resul-
tant expression construct was injected into fertilized oocytes from superovulated C57BL6/J
mice according to the standard procedure. The injected oocytes were transferred to the ovi-
ducts of pseudopregnant mice. The F0 generation was screened for the integration of the trans-
gene by polymerase chain reaction (PCR) of tail genomic DNA with the sense primer 5’-AAC
CGG AAG CTG TTG ATA CTG and the antisense primer 5’-CTC AGT GGT ATT TGT GAG
CCA, which amplified 315-bp DNA product. TG mice were mated with C57BL6/J mice and
three lines were established. Mice were housed in a temperature-controlled conventional facil-
ity (24˚C) under a 12:12h light-dark cycle with free access to regular chow and water at Insti-
tute for Experimental Animal, Advanced Science Research Center, Kanazawa University.
Col1α2-EGFP mice were generated as previously described [13]. To obtain S1PR1-overexpres-
sing ColIα2-EGFP transgenic mice, S1PR1-TG mice and ColIα2-EGFP TG mice were crossed.
All procedures were conducted in accordance with Fundamental Guidelines for Proper Con-
duct of Animal Experiment and Related Activities in Academic Research Institutions under
the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology of
Japan approved by Committee on Animal Experimentation of Kanazawa University (Approval
NO. 44103–1).
Chronic treatment of mice with pharmacological agents
Six week-old TG mice were given candesartan (CDS) (10mg/kg/day in drinking water, a gift
from Takeda Pharmaceutical Company (Osaka, Japan)) or cilazapril (10mg/kg/day in drinking
water, a gift from Eisai. Co. Ltd. (Tokyo, Japan)) for 18 weeks. At the end of the administration
period, mice were subjected to echocardiography and then euthanized by an excess dose of
pentobarbital, followed by morphological analysis of cardiac hypertrophy and fibrosis. In
chronic Ang II infusion experiments, a subpressor dose of Ang II (0.3 mg/kg/day) was admin-
istered into 12-week-old C57BL6/J wild-type mice for 14 days by using osmotic mini-pump
(Alzet, Cupertino, CA). Physiological saline was administered into control mice. For in vivo
IL-6 neutralization, mice received intraperitoneal injections of 100μg rat anti-mouse IL-6 mAb
(clone MP5-20F3) (R&D Systems) in 0.2 ml Dulbecco’s phosphate-buffered saline (PBS). Rat
IgG1 (clone R3-34) (R&D Systems) was administered as isotype-matched control. Administra-
tion of antibodies was started at 8-weeks and conducted every two weeks until 12-weeks.
Blood pressure measurement and echocardiography
Systolic and diastolic blood pressure of conscious mice was non-invasively measured by a tail
cuff method using Softron BP98A (Softron Co. Ltd., Tokyo, Japan) as described previously.
Mice that were anesthetized with pentobarbital (60 mg/kg) underwent echocardiography
using an ultrasonography (Agilent Technology SONOS 5500). A 12-MHz linear ultrasound
transducer (S 12) was applied to depilated left anterior chest wall. M-mode measurements of
the left ventricular (LV) internal diameter, the interventricular septal dimension (IVSd), and
the posterior wall dimension (PWd) were taken from more than five beats and averaged. LV
end-diastolic diameter (EDD) was measured at the time of the apparent maximal LV diastolic
dimension. LV end-systolic diameter (ESD) was measured at the time of the most anterior sys-
tolic excursion of the posterior wall. Percent fractional shortening (%FS) was calculated as
(EDD-ESD)/EDD x 100.
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Northern blot analysis and quantitative real-time polymerase chain
reaction (PCR)
Total RNA was isolated from various organs by using RNeasy (Qiagen). The mRNA expres-
sion of S1PR1, S1PR2, S1PR3, atrial natriuretic peptide (ANP), brain natriuretic peptide
(BNP), β-myosin heavy chain (βMHC), collagen I α-1 chain, skeletal muscle α-action
(αSKMA), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control
was analyzed by Northern analysis as described previously. The expression of S1PR1, S1PR2
and S1PR3, was also analyzed by conventional reverse transcription-PCR as described previ-
ously. Real-time Quantitative PCR analysis was performed using the ABI PRISM 7300
sequence detection system (Applied Biosystems, Foster, CA). The following primers and
TaqMan probes (Applied Biosystems) were used: sphingosine kineses (SphK)-1 (Sphk1,
Mm00448841_g1) and -2 (Sphk2, Mm00445021_m1), S1PR1 (S1pr1, Mm02619656_s1),
S1PR2 (Edg5, Mm02620208_s1), S1PR3 (S1pr3, Mm02620181_s1), angiotensinogen
(Agt, Mm00599662_m1), angiotensin converting enzyme (Ace, ID# Mm00802048_m1),
AT1 (Agtr1, ID# Mm00507771_m1), AT2 (Agtr2, ID# Mm01341373_m1), IL-6 (Il6,
Mm99999064_m1), endothelin-1 (Edn1, Mm00438656_m1), insulin-like growth factor-I
(IGF-I) (Igf-1, Mm00439560_m1), cardiotrophin-1 (CT-1, Mm00432772_m1), leukemia
inhibitory factor (LIF) (Lif, Mm00434762_g1), LIF receptor (LIFR) (Lifr, Mm00442942_m1),
GP130 (Lrpprc, Mm00511512_m1), and transforming growth factor-β1 (TGF−β1) (Tgf-β1,
Mm00441726_m1). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Gapdh,
Mm03302249_g1) was used as an endogenous control. The cycling condition was pro-
grammed as follows: activation of AmpErase uracil-N-glycosylase for prevention of carryover
contamination at 50˚C for 2 min, activation of AmpliTaq Gold DNA polymerase at 95˚C for
10 min, 40 cycles of denaturation at 95˚C for 15 s and annealing/extension at 60˚C for 1 min.
ΔCt was calculated as (gene of interest Ct)−(GAPDH Ct) using Sequence detector (Applied
Biosystems). The relative quantity of mRNA of gene of interest was calculated by ΔΔCt calcula-
tion as 2−((ΔCt of treated sample)− (ΔCt of control sample)). The amplification efficiencies of the target
and the endogenous reference were confirmed by observing the equal relationship between
cDNA dilution and ΔCt. All experiments included negative controls consisting of no cDNA
for each primer pair.
Western blot analysis
The homogenates of hearts were prepared in ice cold heart homogenizing buffer containing
150 nmol/L NaCl, 5 mmol/L EDTA, 50mmol/L Tris/HCl (pH 7.5), 1 mmol/L Na3VO4,
10mmol/L NaF, 1% Triton X 100, 10% glycerol, 1mmol/L phenylmethylsulfonylfluoride and
10mg/ml each of leupeptin and aprotinin. After centrifugation at 3000 x g, the supernatant
devoid of nuclei and debris were centrifuged at 10,000 x g for 10 min. The resultant superna-
tant was mixed with 4 x laemmli’s sample buffer at the ratio of 3:1, followed by the separation
on the 10% SDS-polyacrylamide gel electrophoresis. Separated proteins were electro-trans-
ferred onto Immobilon-P (Millipore), and probed by rabbit polyclonal anti-Thr202, Tyr204-
phosphorylated-ERK antibody (1:1000, Cell Signaling), rabbit polyclonal anti-ERK antibody
(1:1000, Cell Signaling), rabbit polyclonal Tyr705-phosphorylated-STAT3 (1:1000 Cell Signal-
ing) and rabbit S1PR1 C-terminus (1:1000, a kind gift from Dr. S. Mandala at Merck). The
band density of ERKs (p42 and p44) was quantified by using Image J software (NIH), corrected
for that of total ERK, and expressed as multiples of the values in control groups, which was
expressed as 1.0.
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Isolation of mouse cardiac fibroblasts and myocytes
Mouse cardiac fibroblasts and myocytes were isolated by enzymatic digestion with collagenase
and trypsin. Briefly, 2 hearts were isolated and dissected free of vessels and atria. The cannula
was inserted into ascending aorta, and the hearts were perfused for 4 minutes with the collage-
nase buffer that contained (in wt/vol) 0.3% collagenase type II (Worthington), and 0.05% tryp-
sin (Worthington) in Krebs buffer at 37˚C. The digested heart tissues were finely fragmented
by gentle pipetting and filtered by using a mesh (BD Biosciences). The cell suspensions were
centrifugated at 400 x g and resuspended in Dulbecco’s modified Eagle’s minimal essential
medium (DMEM) containing 10% fetal bovine serum. The suspended cells were plated, and 1
h later non-adherent cells were collected. Adherent cardiac fibroblasts were expanded by dis-
persing with trypsin/EDTA solution on reaching confluence and replating at the split ratio of
1:4. Characteristic fibroblasts morphology was visually confirmed under a light microscope.
Nearly 100% of the cells were positive for anti-vimentin staining. Because the phenotype of
fibroblasts can be influenced by the growth condition including the passage number, fibro-
blasts at the passage 1 to 3 were used for the present experiments.
Histological analysis, immunohistochemistry, and immunofluorescence
Mice were euthanized by intraperitoneally injecting an excess dose of pentobarbital. Serial
horizontal sections of acetone-fixed, fresh-frozen sections of hearts were subjected to immuno-
fluorescence using anti-αSMA (clone 1A4, Sigma), anti-S1PR1, anti-CD31, and anti-GFP anti-
bodies. The samples were examined using an inverted fluorescence microscope (Olympus
IX70) under a PlanApo ×40/NA0.95 objective or a confocal laser-scanning microscope (Zeiss
Axiovert 200M with LSM5 Pascal) equipped with a PlanApo ×63/NA1.4 oil-immersion objec-
tive. The mean cross-sectional cardiomyocyte areas were calculated by measuring 100 cells per
specimen that had been subjected to silver impregnation staining. Fibrotic areas were deter-
mined by calculating Azan staining—positive area over total areas by using Image J software.
Determination of Ang II and IL-6 in the conditioned media of cardiac
fibroblasts
The serum-free culture media (2ml per dish) were collected from dishes with or without treat-
ment of the cells with S1P (100nmol/L) and CDS (1μmol/L) for 24 h. Ang II concentration was
determined by radioimmunoassay using two antibodies specific for Ang II (SRL Co., Hachioji,
Japan). IL-6 concentrations were determined with an ELISA kit (R&D Systems).
Statistics
All data are shown as means +/- SEM. One-way ANOVA was followed by a post hoc Bonfer-
roni-Dunn’s comparison test to determine statistical significance of differences between mean
values. Unpaired t-test was performed for the comparison between two groups in Fig 1B, 1C,
1D and 1E, S1 Table, and S1, S4 and S6B Figs. For all statistical comparisons, p<0.05 was con-
sidered significant.
Results
αSMA promoter-driven S1PR1 overexpression induced cardiac
hypertrophy and fibrosis with impaired cardiac function
Chronic Ang II infusion into wild-type (WT) mice increased the cardiac mRNA expression
of S1PR1, SphK1 and αSMA but not S1PR2, S1PR3 or SphK2 (S1 Fig). The observations
Myofibroblastic S1PR1 and cardiac hypertrophy
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Fig 1. Transgenic overexpression of S1PR1 induces pathological cardiac hypertrophy. (A) Gross views
and HE-stained cross-sections of the hearts from WT and TG mice. (B) The HW/BW ratio in 8- to 32-week-old
WT and TG mice. n = 7 mice per group. *, p<0.05 and **, p<0.01. (C) Silver-staining of myocardial sections of
12-week-old WT and TG mice (right). Quantified data of mean cross sectional area of cardiomyocytes (left). (D)
Images of representative isolated cardiomyocytes from WT and TG mice at 12 weeks (left). Quantification of cell
areas of isolated cardiomyocytes (right). (E) Azan staining of myocardial sections of 24-week-old WT and TG
mice (left). Quantified data of fibrotic areas in Azan stained sections of the hearts (right). (F) Northern blot
analysis of mRNAs of natriuretic peptides ANP and BNP, fetal contractile proteins βMHC and αSKA and type I
collagen α1 chain.
https://doi.org/10.1371/journal.pone.0182329.g001
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prompted us to investigate a role of S1PR1 in cardiac remodeling. We generated TG mice
overexpressing S1PR1 under the control of the αSMA promoter and established three inde-
pendent TG mouse lines (line 4, 5 and 11). Analysis of S1PR1 mRNA expression in various
organs of line 4 TG mice shows that S1PR1 transgene mRNA is expressed in most of organs
including lung, intestine, heart and kidney (Panel A in S2 Fig). The expression levels of S1PR1
transgene in hearts of line 4 and 11 mice were slightly higher compared with endogenous
S1PR1, but that in line 5 mice was much lower ((Panel B in S2 Fig). Accordingly, the protein
level of S1PR1 in heart of line 4 was greater than in WT mice (Panel C in S2 Fig). Anti-S1PR1
immunohistochemical staining showed enhanced S1PR1 expression in the vascular wall of
heart and interstitial cells compared with WT mice (Panels D-G in S2 Fig), S1PR1 expression
was increased in the aortic media, and the smooth muscle layers of bronchi, intestine, urinary
bladder and uterus of TG mice compared with WT mice (Panel H in S2 Fig). Line 4 mice were
employed for most of the analyses in the following study.
All three lines of TG mice developed postnatal bi-ventricular cardiac hypertrophy, which
became maximal by 15-weeks (Fig 1A and 1B), with hypertrophy being more severe in lines 4
and 11 than in line 5 TG mice. Cardiac hypertrophy in TG mice was diffuse with hypertrophy
of the interventricular septum and the free wall of both right and left ventricles. Individual car-
diomyocytes in TG mice were hypertrophic compared with those from WT mice (Fig 1C).
Cardiomyocytes isolated from TG mice displayed greater cell area compared with those from
WT mice (Fig 1D). In TG heart at 24-weeks but not 12 weeks, increased diffuse accumulation
of collagen fibers in both interstitial and perivascular areas was observed compared with WT
mice (Fig 1E). Consistent with these pathological changes in TG heart, the mRNA expression
of collagen I α-1 chain and the embryonic genes, which include atrial natriuretic peptide
(ANP), brain natriuretic peptide (BNP), β-myosin heavy chain (β-MHC) and skeletal muscle
α-actin, was elevated markedly in lines 4 and 11 TG mice and modestly in line 5 compared
with WT mice (Fig 1F). Echocardiographic determinations showed a decreased %fractional
shortening (%FS) without ventricular dilatation in line 4 mice at 24-weeks but not 12-weeks
compared with line 4 TG mice (S3 Fig), indicating impaired contractile function in TG mice.
TG mice were normotensive at 12-weeks, suggesting that ventricular hypertrophy was not a
result of pressure overload (S1 Table). The mean life-span of TG mice was not different from
that of WT mice up to 24-weeks.
Cardiac fibroblasts are non-vascular cells that overexpress S1PR1 in
heart of TG mice
We determined S1PR1 expression in the heart in both WT and TG mice at three stages,
namely the pre-hypertrophic stage (8-week-old), the hypertrophic stage (15-week-old), and
the hypertrophic and fibrotic stage (24-week-old), using anti-S1PR1 immunofluorescent stain-
ing. At 8-weeks, we detected many S1PR1-positive cells diffusely in the myocardium of both
WT and TG mice (Fig 2A). Because S1PR1 is known to be expressed in vascular endothelial
cells, we performed anti-S1PR1 and anti-CD31 (endothelial marker) double immunofluores-
cent staining. Virtually all S1PR1-positive cells in WT mouse heart are CD31-positive endothe-
lial cells (Fig 2B). In TG mouse heart, most S1PR1-positive cells are CD31-positive. However,
some S1PR1-positive cells are CD31-negative (arrowheads in Fig 2B) and show different mor-
phology from CD31- and S1PR1-double positive endothelial cells. Anti-S1PR1 and anti-αSMA
double immunostaining showed that S1PR1- and αSMA-double positive cells are observed in
TG heart (arrowheads in Fig 2A). These double positive cells are scattered and solitary, and so
do not look like vascular wall cells. Therefore, these αSMA-positive cells are most likely myofi-
broblasts. Thus, at the earlier prehypertrophic stage, some fibroblasts are already activated as
Myofibroblastic S1PR1 and cardiac hypertrophy
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Fig 2. S1PR1 is expressed in fibroblasts in heart of TG mice. Double immunofluorescence staining of ventricular
sections from 8- (A, B), 15- (C, D), and 24-week-old (E, F) WT and TG mice. (A, C and E) Anti-αSMA and anti-S1PR1
staining. In both WT and TG mice, S1PR1 is diffusely expressed in αSMA-negative cells. However, some scattered and
solitary S1PR1- and αSMA-double positive apparently non-vascular wall cells (arrowheads) are observed in TG mice
but not WT mice, and these double positive non-vascular wall cells increase with aging in TG mice. The arrows in C
denote S1PR1- and αSMA-double positive vascular wall cells in WT and TG mice. (B, D and F) Anti-S1PR1 and anti-
CD31 staining. In both WT and TG mice, S1PR1 is diffusely expressed in CD31-positive vascular endothelial cells.
Myofibroblastic S1PR1 and cardiac hypertrophy
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suggested by their αSMA expression and exhibit the αSMA promoter-driven overexpression
of S1PR1. At 15-weeks, the S1PR1-positive but CD31-negative cells are more frequently
observed in TG heart compared with 8-week-old TG heart, but hardly seen in WT heart (Fig
2D). The scattered and solitary S1PR1- and αSMA-double positive cells are observed in
15-week-old TG heart (Fig 2C). Less frequently, S1PR1- and αSMA-double positive cells were
observed in the vascular wall of arterioles in both WT and TG hearts (Fig 2C). These double
positive cells in the vascular wall are likely smooth muscle or pericytes. At 24-weeks, the
S1PR1-positive but CD31-negative cells, and the scattered type of S1PR1- and αSMA -double
positive cells in TG heart are more abundant compared with 8- and 15-weeks (Fig 2E, 2F and
2G), and they are often clustered (Fig 2E, arrowheads). In 24-week-old S1PR1-TG mice with
the ColI α2-EGFP background, EGFP-positive fibroblasts were intensely S1PR1-positive (Fig
2H), providing further evidence that cardiac fibroblasts overexpress S1PR1 in TG mice.
Cardiac hypertrophy in TG mice is dependent on Ang II-AT1
In TG mice hearts, the mRNA expression of angiotensin converting enzyme-1 (ACE) but not
angiotensinogen, AT1 or AT2 was elevated compared with WT mice hearts (S4 Fig). There-
fore, we determined the effect of pharmacological AT1 blockade on cardiac remodeling in TG
mice. Administration of the AT1-selective antagonist candesartan (CDS), which started at
6-weeks, nearly abolished both cardiac hypertrophy and fibrosis with improvement of %FS at
24-weeks (Fig 3A–3D). The ACE inhibitor cilazapril also prevented cardiac hypertrophy in TG
mice (S5 Fig). Consistent with the resolution of cardiac hypertrophy and fibrosis by blockade
of the Ang II-AT1 pathway, the upregulation of mRNA expression of ANP, BNP, and β-MHC
was all reversed by CDS (Fig 3E). Compared with WT mice hearts, TG mice hearts showed
increased ERK phosphorylation, which was abolished by administration of CDS (Fig 3F).
Cardiac hypertrophy induced by S1PR1 overexpression in fibroblasts is
mediated through Ang II-dependent production of IL-6
The mRNA expression of IL-6, a hypertrophic mediator, in TG mice hearts was 5-fold
increased with WT mice hearts (Fig 3G). In addition, the mRNA expression of leukemia inhib-
itory factor (LIF), another IL-6 family of cytokine, was slightly increased in TG mice hearts
compared with WT mice hearts (Panel A in S6 Fig). In contract, cardiac mRNAs of cardiotro-
phin-1, the central signal-transducing receptor GP130 for IL-6 family cytokines, LIF receptor,
insulin-like growth factor-I or TGF-β1 were not different between TG and WT mice (Panels A
and B in S6 Fig). Notably, administration of CDS abolished upregulation of IL-6 mRNA in TG
mice hearts (Fig 3G).
We isolated fibroblasts from WT and TG mouse hearts. Nearly all cells from both WT and
TG mice were positive for S1PR1 as well as αSMA (Fig 4A) with higher expression of S1PR1 in
fibroblasts from TG mice. In contrast, the mRNA of S1PR1 transgene was hardly detectable in
cardiomyocytes from TG mice (Panel B in S7 Fig). The mRNA expression of S1PR2 and
S1PR3 was similar in fibroblasts from WT and TG mice hearts (Panel A in S7 Fig).
The level of Ang II peptide in the conditioned media of cardiac fibroblasts from TG mice
was 2.5-fold greater compared with that in fibroblasts from WT mice (Fig 4B). S1P treatment
However, some S1PR1-positive cells are CD31-negative (arrowheads) and these S1PR1-positive and CD31-negative
cells increase with aging in TG mice. (G) Quantified data of scattered and solitary αSMA- and S1PR1-positive cells. HF,
high power field. **, p<0.01. (H) Anti-EGFP and anti-S1PR1 double immunofluorescence staining of ventricular
sections from 24-week-old WT and S1PR1-TG mice with the ColI α2-EGFP background. S1PR1 is overexpressed in
EGFP-positive cells (arrowheads) in TG mice but not WT mice.
https://doi.org/10.1371/journal.pone.0182329.g002
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Fig 3. An AT1 blocker inhibits ventricular hypertrophy and fibrosis in TG mice. Administration of the
AT1 blocker candesartan (CDS) was started at 6-weeks and continued for 18 weeks. (A) Gross views and
HE-stained sections of the hearts from WT, non-treated TG, and CDS-treated TG mice at 24-week-old (left
panel), and the HW/BW ratio in each mouse group (right panel). n = 6 mice per group. (B) Azan staining of
myocardial sections of WT, non-treated TG, and CDS-treated TG mice at 24-weeks (upper panel) and
quantified data (lower panel). n = 6 per group. (C) Silver-staining of myocardial sections of WT, non-treated
TG, and CDS-treated TG mice at 24-weeks (upper panel) and quantified data (lower panel). n = 6 per group.
(D) %FS in WT, non-treated TG, and CDS-treated TG mice at 24-weeks as evaluated with echocardiography.
N = 6 per group. (E) Effects of CDS on increased mRNA expression of ANP, BNP and βMHC in the heart of
TG mice at 24-weeks. N = 5 mice per group. (F) Phosphorylation of ERK in heart. The extracts of the hearts
Myofibroblastic S1PR1 and cardiac hypertrophy
PLOS ONE | https://doi.org/10.1371/journal.pone.0182329 August 3, 2017 10 / 19
from WT, non-treated TG, and CDS-treated TG mice at 24-weeks was analyzed by Western blotting using
anti-phospho ERK (p-ERK) antibody. n = 5 mice per group. (G) Effects of CDS on mRNA expression of IL-6 in
the heart of TG mice at 24-weeks. n = 5 mice per group. In A-G, *, p<0.05, and **, p<0.01.
https://doi.org/10.1371/journal.pone.0182329.g003
Fig 4. Cardiac fibroblasts overexpressing S1PR1 release a greater amount of Ang II. (A) Double
immunofluorescence staining of fibroblasts isolated from 24-week-old WT and TG mice, using anti-αSMA and
anti-S1PR1 antibodies. S1PR1 is more abundantly expressed in fibroblasts from TG mice compared with WT
mice. (B) Ang II peptide levels in the conditioned media of WT and TG fibroblasts cultured in the presence and
absence of S1P (100 nmol/L) without serum for 24 h. n = 6 per group. (C) Real-time PCR analysis of mRNAs
of ACE, angiotensinogen, AT1 and AT2 in WT and TG fibroblasts. In B and C, *, p<0.05 and **, p<0.01.
https://doi.org/10.1371/journal.pone.0182329.g004
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of fibroblasts did not affect Ang II release. ACE mRNA levels were increased in S1P-treated,
TG mouse-derived fibroblasts compared with WT fibroblasts whereas those of angiotensino-
gen, AT1 and AT2 were rather decreased in TG fibroblasts than in WT fibroblasts (Fig 4C).
We next studied the effects of S1P and AT1 on IL-6 release from isolated cardiac fibroblasts.
S1P treatment stimulated IL-6 release in TG fibroblasts but not WT fibroblasts (Fig 5A). The
addition of CDS abolished S1P-induced stimulation of IL-6 release. S1P also increased IL-6
mRNA in TG fibroblasts but not WT fibroblasts, which was inhibited by the addition of CDS
(Fig 5B). Finally, we tested the effects of administration of a specific IL-6 neutralizing antibody
on cardiac hypertrophy and STAT3 phosphorylation in TG mice. The control TG mouse
group received injections of isotype-matched control IgG. The tyrosine phosphorylation level
of STAT3, a key signaling molecule downstream of IL6, in the heart was elevated in control
IgG-given TG mice at 12-weeks compared with WT mice (Fig 5C). Administration of anti-IL-
6 antibody abolished an increase in STAT3 phosphorylation in TG mouse heart. Anti-IL-6
antibody also abolished an increase in the heart weight (HW) / body weight (BW) ratio and
the interventricular septum dimension (IVSd) and left ventricular posterior wall dimension
(PWd) in TG mice at 12-weeks (Fig 5D and 5E).
Discussion
This study demonstrates a novel fibroblast-mediated effect of S1PR1 on cardiac remodeling.
Augmented S1PR1 action due to αSMA promoter-driven S1PR1 overexpression in mice leads
to cardiac hypertrophy and fibrosis with reduced contractility in the absence of hemodynamic
stress. In TG mouse heart, S1PR1 is overexpressed in hyperplastic fibroblasts/myofibrablasts
but not cardiomyocytes. Mechanistically, S1PR1-mediated cardiac hypertrophy is character-
ized by total dependence on Ang II-AT1 axis and IL-6. Ang II-AT1 is involved in production
of IL-6 in fibroblasts in a paracrine/autocrine manner.
During cardiac remodeling, fibroblasts in heart undergo the characteristic phenotypic
changes to differentiate into myofibroblasts, which express smooth muscle-specific contractile
protein αSMA [14]. We employed the αSMA promoter to overexpress S1PR1, a receptor
which stimulates cell proliferation and migration in fibroblasts [4, 11]. As expected, the major-
ity of CD31-negative and S1PR1-positive cells in TG mice hearts were also positive for the
fibroblast/myofibroblast markers, αSMA and collagen I α-2 [9, 15]. The expression at a single
cell level of S1PR1 as well as αSMA was more intense in fibroblasts from TG mice compared
with WT mice, indicating that the αSMA promoter was active in fibroblasts from TG mice.
Cardiac fibroblasts express a much higher level of sphingosine kinase-1 compared with cardio-
myocytes [16], suggesting that S1PR1 in cardiac fibroblasts may be effectively activated by
autocrine/paracrine S1P in TG mice. Consistent with these, fibroblast/myofibroblasts were
hyperplastic in TG heart as indicated by the greater anti-αSMA positive cells. Thus, αSMA
promoter-driven S1PR1 overexpression facilitated proliferation of cardiac fibroblasts with the
myofibroblastic phenotype in TG mice.
Cardiac fibroblasts regulate phenotypes of cardiomyocytes and fibroblasts themselves
through releasing a variety of paracrine humoral factors including Ang II, TGF-β, IGF-I and
IL-6 [17]. A recent study [18] revealed that fibroblasts play an essential role in hypertrophic
response to pressure overload by releasing IGF-I. Cardiac fibroblasts have all the components
of the renin-angiotensin system (RAS) [19]. In the present study, fibroblasts from TG mouse
heart expressed a higher mRNA level of ACE and produced a larger amount of Ang II, which
was crucially involved in cardiac remodeling in TG mice via AT1. Because Ang II induces
upregulation of S1PR1 (S1 Fig), there may be an autocrine/paracrine positive feedback loop
comprising S1PR1-Ang II-AT1. Besides Ang II, we observed 3 to 5 fold increase in IL-6
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Fig 5. IL-6 is involved in cardiac hypertrophy in TG mice. (A) IL-6 peptide levels in the conditioned media of fibroblasts, which were
isolated from 24-week-old WT and TG mice and cultured in the presence and absence of S1P (100 nmol/L) and CDS (1 μmol/L) without
serum for 24 h. n = 8. (B) Expression of IL-6 mRNA in cardiac fibroblasts isolated from 24-week-old WT and TG mice. Fibroblasts were
cultured in the presence and absence of S1P (100 nmol/L) and CDS (1 μmol/L) without serum for 24 h. n = 8. (C-E) Effects of administration
(every two weeks) of neutralizing anti-IL-6 antibody or control isotype-matched IgG, which was started at 8-weeks, and mice were sacrificed
at 12-weeks. (C) The effects of anti-IL-6 antibody administration on the phosphorylation of STAT3 were determined at 12-weeks. Mice
received i.p. injections of anti-IL6 antibody or isotype—matched control IgG as described in Materials and methods. (D) Effects of anti-IL-6
antibody administration on the HW/BW ratio was determined at 12-weeks. n = 5 mice per group. (E) Effects of anti-IL-6 antibody
administration on IVSd and PWd. Mice received anti-IL-6 antibody or control IgG as described in C, and underwent echocardiographic
analysis at 12-week-old. n = 5 mice per group.
https://doi.org/10.1371/journal.pone.0182329.g005
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mRNA in TG mouse heart and S1P-induced IL-6 peptide release from TG fibroblasts com-
pared with WT mice. None of the other hypertrophic mediators and their receptors examined
was not elevated, except LIF which showed a slight increase in TG heart. Notably, the increase
in IL-6 mRNA expression in TG mouse heart was dependent on AT1. IL-6 has a hypertrophic
activity for cardiomyocytes both in vitro and in vivo [20, 21], and is involved in exogenous
Ang II-induced cardiac hypertrophy [22]. These previous observations suggest that IL-6 is a
downstream effector of Ang II signaling to mediate cardiac hypertrophy. In the present study,
blockade of IL-6 action by the neutralizing antibody abolished hypertrophy in TG mice.
Therefore, it is likely that augmented S1PR1 action in fibroblasts stimulated release of Ang II
and thereby IL-6, culminating in hypertrophy. Alternatively, it might also be possible that
S1PR1 and AT1 could form the positive feedback loop to stimulate each other or that S1PR1
and AT1 could operate in parallel pathways, which are both necessary for the development of
the hypertrophic phenotype in TG mice, with the interaction of stimulating each pathway.
Further study is required for fully understanding the interplays of S1PR1 and AT1.
We observed that TG mouse-derived fibroblasts showed enhanced Ang II production
under the serum-free culture condition, compared with wild-type fibroblasts (Fig 4B). Differ-
ently from the case of IL-6 production, which will be discussed below, in vitro treatment of the
cells with exogenous S1P did not increase Ang II production in TG fibroblasts. Fibroblasts
from TG mice hearts exhibited enhanced differentiation toward myofibroblasts as demon-
strated by increased αSMA expression (Fig 2). The upregulated αSMA expression in fibro-
blasts was maintained at least for the three passages of culture in fibroblasts isolated from TG
mouse heart. Cultured fibroblasts from TG mouse heart also showed upregulation of ACE
gene expression (Fig 4C). Thus, cardiac fibroblasts isolated from TG mice maintains the phe-
notypic changes including altered gene expression of αSMA and ACE in vitro after isolation,
suggesting that cardiac fibroblasts have undergone the S1PR1-mediated phenotypic changes in
vivo. The in vivo phenotypic changes of cardiac fibroblasts may involve the actions of para-
crine and autocrine humoral factors including angiotensin II, IL-6 cytokine family members,
TGFβ and IGF-I (Figs 3–5, S5 and S7 Figs). Alternatively, it is possible that even a low concen-
tration of S1P, which was released into the media from fibroblasts, could be enough to main-
tain the phenotype of increased angiotensin II production.
IL-6 production is driven mainly by two intracellular signaling pathways, STAT3 and NF-
κB pathways. S1PR1 in tumor cells was previously shown to be linked to STAT3 activation,
which contributed to stimulated IL-6 production [23] [24]. Therefore, it is an interesting possi-
bility that S1P stimulation of IL-6 production in TG fibroblasts but not WT fibroblasts (Fig
5A) could be mediated through S1PR1-STAT3 pathway. Importantly, stimulation of IL-6
release by S1P is dependent on AT1. AT1 was previously shown to couple to phosphorylation
of STAT1 and STAT2 via tyrosine kinase JAK2 [25]. Phosphorylated STATs homo-dimerize
or hetero-dimerize and exhibit isoform-specific activities. It may be possible that differential
activation of STAT family members by S1PR1 and AT1 could underlie the cooperative actions
of S1PR1 and AT1 in stimulating IL-6 production. The precise molecular mechanisms of
S1PR1- and AT1-dependent IL-6 release, and possible functional cross talk between S1PR1
and AT1R remain to be clarified.
These are several genetically modified animal models for cardiac hypertrophy, in which the
cardiac RAS is targeted [26]. They are largely the mouse models that aimed at overproducing
Ang II or overexpressing AT1 in cardiomyocytes. The αMHC promoter-driven overexpres-
sion of angiotensinogen, which resulted in a 2-fold increase in cardiac Ang II level, was accom-
panied by bi-ventricular hypertrophy and age-dependent cardiac dysfunction but not fibrosis
[27]. In contrast, αMHC promoter-driven overexpression of ACE [28] or an engineered fusion
protein designed to directly release Ang II [29] in cardiomyocytes did not result in ventricular
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hypertrophy despite of greater increases in cardiac Ang II level compared with the above men-
tioned study [27]. The effects of αMHC promoter-driven overexpression of AT1 are also com-
plicated; transgenic overexpression of AT1 in cardiomyocytes, only when overexpressed at
very high levels, e.g. 200-fold compared with WT mice, resulted in ventricular hypertrophy
[30]. The observations may suggest that increased Ang II generation and AT1 expression in
cardiomyocytes could be rather the limiting factor than the primary determinant in RAS-
mediated hypertrophic effects. Our model is distinct from these genetically modified animal
models in that augmented activation of S1PR1 in fibroblasts results in stimulation of Ang II
generation in fibroblasts. Our model is the first transgenic mouse model in which stimulation
of local RAS in fibroblasts results in ventricular hypertrophy and fibrosis through S1PR1- and
AT1-dependent IL-6 release from fibroblasts. This Ang II-dependent remodeling model spares
other organs and tissues including lung, liver and arteries although the mechanism for this
sparing is unknown presently.
In our recent study [8], we demonstrated that transgenic overexpression of SphK1 in mice
resulted in interstitial cardiac fibrosis but not hypertrophy, which was mediated via S1PR3 but
independent of AT1. S1PR3 signaling in cardiac fibrosis involved reactive oxygen species gen-
eration and TGF-β-Smad2/3 pathway. Cardiac fibroblasts endogenously express S1PR3 and
S1PR2, besides S1PR1 [8, 11]. Therefore, it is possible that in vivo stimulation of fibroblast S1P
receptors in SphK1-transgenic mouse heart might result in relatively dominant activation of
S1PR3, which is different from the present case of transgenic S1PR1-overexpression. Activa-
tion of S1PR3, which couples to Gq and G12/13 unlike S1PR1, might lead to cardiac fibrosis
without hypertrophy. Alternatively, increased cardiac S1P level in SphK1-transgenic mice acti-
vates multiple S1P receptors in both fibroblasts and myocytes, which might bring about the
different outcome from the case of augmented S1PR1 activation in fibroblasts in S1PR1-trans-
genic mice. Besides causing cardiac fibrosis, SphK1 overexpression also exerted a protective
effect from ischemia/reperfusion injury, which was shown to be mediated by S1PR2 and
S1PR3 [8, 11, 31]. The effect of S1PR1 overexpression in fibroblasts against cardiac injury
deserves further investigation.
This study may have the following limitations; 1) the αSMA promoter drives gene expres-
sion in smooth muscle of various organs in adult mice, besides myofibroblasts. Therefore,
the possibility that other αSMA-positive cells to express S1PR1 transgene than myofibro-
blasts could be involved in the development of the phenotype in S1PR1-TG mice cannot be
completely excluded. 2) this study is based on the analyses in S1PR1-transgenic mouse
model. Another loss of function mutation approach using fibroblast-specific S1PR1 gene
deletion would be informative in understanding a role of S1PR1 in cardiac hypertrophy and
may provide a new insight into therapeutic clues for preventing cardiac fibrosis.
Our data show the crucial role of S1PR1-mediated lysophospholipid signaling in cardiac
fibroblasts for cardiac hypertrophy and fibrosis. This S1PR1 action involves stimulation of
local RAS activity and thereby IL-6 generation on fibroblasts. These findings reveal the novel
molecular link for engagement of fibroblasts in cardiac remodeling, pointing to a new thera-
peutic approach for cardiac remodeling. Our TG mice also provide a useful animal model for
studying pathological cardiac hypertrophy, particularly the role of local RAS in cardiac
remodeling.
Supporting information
S1 Fig. Ang II infusion induces hypertrophy and an increase in mRNAs of S1PR1 and
sphingosine kinase-1 in the heart of mice infused with Ang II. Ang II was infused with
osmotic mini-pump for 14 days. (A) The heart weight / body weight (HW / BW) ratio in mice
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receiving vehicle (saline) and Ang II. n = 5 mice per group. (B) Real-time PCR analysis of
mRNAs of S1P receptors, SphKs and aSMA in the hearts of mice. n = 5 mice per group. In A
and B,  p<0.05,  p<0.01.
(TIF)
S2 Fig. Expression of S1PR1 transgene and endogenous S1P receptors in WT and TG
mice. (A) Northern blot analysis of S1P receptors in various organs. S1PR1 transgene is read-
ily detected in lung, intestine, heart, kidney and brain. There is no difference in the endo-
genou gene expression of S1PR1, S1PR2 and S1PR3 between WT and TG mice. (B)
Expression of S1PR1 transgene and endogenous gene in hearts of three TG mouse lines.
Lines 4 and 11 abundantly express S1PR1 transgene whereas line 5 modestly expressed
S1PR1 transgene. (C) Protein expression of S1PR1 and GAPDH (glyceraldehyde 3-phos-
phate dehydrogenase) in heart was determined by western blotting using anti-S1PR1 and
anti-GAPDH antibodies. (D-G) S1PR1 was overexpressed in vascular smooth muscle cells
(arrows) and interstitial cells (arrowhead) in the heart of TG mice. (H) Aortic media, bron-
chus, intestine, urinary bladder and uterus. S1PR1 was overexpressed in the smooth muscle
layers of these organs in TG mice.
(TIF)
S3 Fig. Echocardiographic analysis of hypertrophic hearts from WT and TG mice. (A) end-
diastolic interventricular septal dimension (IVsd). (B) end-diastolic posterior wall dimension
(PWd). (C) end-diastolic left ventricular diameter (EDD). (D) %fractional shortening (% FS).
n = 7~8 mice per group.  P<0.01.
(TIF)
S4 Fig. Cardiac mRNA expression of angiotensin signaling system in WT and TG mice.
Real-time PCR analysis of mRNAs of angiotensinogen, ACE, AT1 and AT2 in WT and TG
hearts. n = 5 mice per group.  p<0.05.
(TIF)
S5 Fig. Blockade of angiotensin system prevents cardiac hypertrophy and fetal gene
expression in TG mice. The ACE inhibitor cilazapril were administered into mice as
described in Methods, and mice were analyzed at 24 weeks. Effect of cilazapril on the HW /
BW ratio in TG mice. n = 5 mice per group.  p<0.05.
(TIF)
S6 Fig. Expression of hypertrophic mediators and receptors in the heart of WT and TG
mice and effects of an AT1 antagonist on their expression. Expression of mRNAs were ana-
lyzed by real-time PCR. (A) Expression of mRNAs of cardiotrophin1, LIF, GP130 and LIFR in
the hearts of WT and TG mice. (B) Effects of CDS on mRNA expression of endothelin1, IGF-I
and TGFβ in the heart of TG mice. n = 5 mice per group. n = 5 mice per group. In (A) and (B),
 p<0.05.
(TIF)
S7 Fig. Expression of S1PR1 in cardiac fibroblasts and cardiomyocytes. (A) Expression of
S1PR1, S1PR2 and S1PR3 in cardiac fibroblasts isolated from WT and TG mice. The expres-
sion of S1P receptor mRNAs Total RNA was determined by reverse transcription-PCR. (B)
The expression of endogenous S1PR1, S1PR1 transgene and internal control GAPDH was
determined by Northern blotting. Total RNA was isolated from cardiomyocytes and heart tis-
sues.
(TIF)
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S1 Table. Characteristics of WT and TG mice.
(TIF)
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